Display options
Cite
Deng Y, Lin N, Wu L, et al. Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment. Exp Ther Med. 2017;14(4):3632-3636doi: 10.3892/etm.2017.4950.
Deng, Y., Lin, N., Wu, L., Jia, Q., & Liu, H. (2017). Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment. Experimental and therapeutic medicine, 14(4), 3632-3636. https://doi.org/10.3892/etm.2017.4950
Deng, Yinghui, et al. "Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment." Experimental and therapeutic medicine vol. 14,4 (2017): 3632-3636. doi: https://doi.org/10.3892/etm.2017.4950
Deng Y, Lin N, Wu L, Jia Q, Liu H. Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment. Exp Ther Med. 2017 Oct;14(4):3632-3636. doi: 10.3892/etm.2017.4950. Epub 2017 Aug 16. PMID: 29042958; PMCID: PMC5639305.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Oct;14(4):3632-3636. doi: 10.3892/etm.2017.4950. Epub 2017 Aug 16.

Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment.

Experimental and therapeutic medicine

Yinghui Deng, Na Lin, Leiyun Wu, Qaing Jia, Hua Liu

Affiliations

  1. Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China.

PMID: 29042958 PMCID: PMC5639305 DOI: 10.3892/etm.2017.4950

Abstract

The present study aimed to determine whether the expression of lectin-like oxidized LDL receptor 1 (LOX-1) could be induced by oxidized low-density lipoprotein (Ox-LDL) and interleukin 1β (IL-1β) in human mesangial cells (HMCs). Oil Red O staining was used to observe the uptake of Ox-LDL by HMCs stimulated with IL-1β, and reverse transcription-quantitative polymerase chain reaction analysis and western blotting were used to examine the expression of LOX-1 in HMC following Ox-LDL and IL-1β treatment. Uptake of Ox-LDL by HMCs was upregulated upon stimulation with IL-1β. Furthermore, Ox-LDL (10-40 µg/ml) treatment induced LOX-1 mRNA and protein expression in a dose-dependent manner. In addition, when HMCs were treated with IL-1β and Ox-LDL, the expression of LOX-1 was enhanced further. These results indicated that inhibiting LOX-1 expression or inhibiting the Ox-LDL/LOX-1 signaling axis may be a potential novel method for treating renal disease.

Keywords: human mesangial cell; interleukin 1β; lectin-like oxidized LDL receptor 1; oxidized low-density lipoprotein

References

  1. Intern Med. 2009;48(4):189-94 - PubMed
  2. Hepatology. 2008 Sep;48(3):770-81 - PubMed
  3. Atherosclerosis. 2007 Nov;195(1):48-56 - PubMed
  4. Methods. 2001 Dec;25(4):402-8 - PubMed
  5. J Am Soc Nephrol. 2000 Oct;11(10):1826-36 - PubMed
  6. J Atheroscler Thromb. 2013;20(2):123-33 - PubMed
  7. Exp Eye Res. 2012 May;98:79-87 - PubMed
  8. BMC Cardiovasc Disord. 2015 Jul 30;15:80 - PubMed
  9. Int J Mol Med. 2010 Nov;26(5):679-90 - PubMed
  10. Kidney Int. 2001 Nov;60(5):1716-25 - PubMed
  11. Cardiol Res Pract. 2012;2012:632408 - PubMed
  12. Am J Physiol Renal Physiol. 2008 May;294(5):F1136-45 - PubMed
  13. J Am Soc Nephrol. 2003 Mar;14 (3):593-600 - PubMed
  14. J Biochem Biophys Methods. 2007 Aug 1;70(5):709-11 - PubMed
  15. Oncotarget. 2016 Apr 26;7(17 ):24361-73 - PubMed
  16. Asia Pac J Clin Oncol. 2016 Jun;12 (2):174-80 - PubMed
  17. Adv Chronic Kidney Dis. 2014 Sep;21(5):408-16 - PubMed
  18. Lipids Health Dis. 2015 Dec 30;14:167 - PubMed
  19. Methods Mol Biol. 2014;1192:229-37 - PubMed
  20. Dtsch Med Wochenschr. 2010 Feb;135(7):308-12 - PubMed
  21. Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1116-22 - PubMed

Publication Types